重药控股：盐酸普拉格雷片获临床试验批准

Core Viewpoint - Zhongyao Holdings (000950) announced that its subsidiary, Zhongyao Co., has received the clinical trial approval notice from the National Medical Products Administration for the drug Prasugrel Hydrochloride Tablets, which will soon commence clinical trials [1] Company Summary - The drug is indicated for the prevention of thrombus formation in patients undergoing percutaneous coronary intervention for acute coronary syndrome, stable angina, and old myocardial infarction [1]